The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bergmann, C. C.
Right arrow Articles by Buckwold, S. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bergmann, C. C.
Right arrow Articles by Buckwold, S. L.

The Journal of Immunology, Vol 157, Issue 8 3242-3249, Copyright © 1996 by American Association of Immunologists


ARTICLES

Flanking residues alter antigenicity and immunogenicity of multi-unit CTL epitopes

CC Bergmann, Q Yao, CK Ho and SL Buckwold
Department of Neurology, University of Southern California School of Medicine, Los Angeles 90033, USA.

CD8+ CTL responses constitute a critical component for vaccines developed to eliminate intracellular pathogens. One approach to achieve broad CTL diversity is based on genetically linking immunogenic peptides from multiple proteins to form poly-epitope Ags. To address the influence of flanking residues on class I Ag presentation, H-2d- restricted HIV-1 and mouse hepatitis virus CTL epitopes were linked via various spacer residues. The resulting 20 to 31 amino acid peptides were expressed using recombinant vaccinia viruses to monitor both CTL recognition and induction. Our data indicate that recognition is profoundly influenced by the nature of intervening residues forming carboxyl-terminal flanks for one and amino-terminal flanks for the other epitope. Flanking amino acids with aromatic (tyrosine), basic (lysine), and small aliphatic side chains (alanine) supported efficient CTL recognition of both epitopes. By contrast, acidic and helix breaking residues (glycine, proline) specifically inhibited recognition of the adjacent amino-terminal epitope. Flanking residues inhibitory for recognition were also detrimental for CTL induction, suggesting similar processing mechanisms in vitro and in vivo. The ratios of peptide-specific CTL precursors primed by the tandem epitopes varied up to 50-fold depending on molecular context. These data demonstrate a substantial role of carboxyl-flanking residues in governing the efficiency of class I Ag presentation both in vitro and in vivo. The dramatic influence of flanking residues on the hierarchy of CTL responses indicates that CTL induction by poly-epitope Ags can be optimized by strategically linking epitopes via selection of appropriate spacer residues.


This article has been cited by other articles:


Home page
J. Immunol.Home page
C. F. Towne, I. A. York, L. B. Watkin, J. S. Lazo, and K. L. Rock
Analysis of the Role of Bleomycin Hydrolase in Antigen Presentation and the Generation of CD8 T Cell Responses
J. Immunol., June 1, 2007; 178(11): 6923 - 6930.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
P. Daftarian, S. Ali, R. Sharan, S. F. Lacey, C. La Rosa, J. Longmate, C. Buck, R. F. Siliciano, and D. J. Diamond
Immunization with Th-CTL Fusion Peptide and Cytosine-Phosphate-Guanine DNA in Transgenic HLA-A2 Mice Induces Recognition of HIV-Infected T Cells and Clears Vaccinia Virus Challenge
J. Immunol., October 15, 2003; 171(8): 4028 - 4039.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Boissonnas, O. Bonduelle, A. Antzack, Y.-C. Lone, C. Gache, P. Debre, B. Autran, and B. Combadiere
In Vivo Priming Of HIV-Specific CTLs Determines Selective Cross-Reactive Immune Responses Against Poorly Immunogenic HIV-Natural Variants
J. Immunol., October 1, 2002; 169(7): 3694 - 3699.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
V. Novitsky, H. Cao, N. Rybak, P. Gilbert, M. F. McLane, S. Gaolekwe, T. Peter, I. Thior, T. Ndung'u, R. Marlink, et al.
Magnitude and Frequency of Cytotoxic T-Lymphocyte Responses: Identification of Immunodominant Regions of Human Immunodeficiency Virus Type 1 Subtype C
J. Virol., September 11, 2002; 76(20): 10155 - 10168.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
Y.-Z. Wu, J.-P. Zhao, Y. Wan, Z.-C. Jia, W. Zhou, J. Bian, B. Ni, L.-Y. Zou, and Y. Tang
Mimovirus: a Novel Form of Vaccine That Induces Hepatitis B Virus-Specific Cytotoxic T-Lymphocyte Responses In Vivo
J. Virol., September 11, 2002; 76(20): 10264 - 10269.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
J. R. Currier, M. deSouza, P. Chanbancherd, W. Bernstein, D. L. Birx, and J. H. Cox
Comprehensive Screening for Human Immunodeficiency Virus Type 1 Subtype-Specific CD8 Cytotoxic T Lymphocytes and Definition of Degenerate Epitopes Restricted by HLA-A0207 and -CW0304 Alleles
J. Virol., April 16, 2002; 76(10): 4971 - 4986.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
R. F. Rich and W. R. Green
Characterization of the Fas Ligand/Fas-Dependent Apoptosis of Antiretroviral, Class I MHC Tetramer-Defined, CD8+ CTL by In Vivo Retrovirus-Infected Cells
J. Immunol., March 15, 2002; 168(6): 2751 - 2758.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
D. Lopez, Y. Samino, U. H. Koszinowski, and M. Del Val
HIV Envelope Protein Inhibits MHC Class I Presentation of a Cytomegalovirus Protective Epitope
J. Immunol., October 15, 2001; 167(8): 4238 - 4244.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
D. Lopez, B. C. Gil-Torregrosa, C. Bergmann, and M. Del Val
Sequential Cleavage by Metallopeptidases and Proteasomes Is Involved in Processing HIV-1 ENV Epitope for Endogenous MHC Class I Antigen Presentation
J. Immunol., May 15, 2000; 164(10): 5070 - 5077.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. X. Y. Mo, S. F. L. van Lelyveld, A. Craiu, and K. L. Rock
Sequences That Flank Subdominant and Cryptic Epitopes Influence the Proteolytic Generation of MHC Class I-Presented Peptides
J. Immunol., April 15, 2000; 164(8): 4003 - 4010.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
C. Brander, O. O. Yang, N. G. Jones, Y. Lee, P. Goulder, R. P. Johnson, A. Trocha, D. Colbert, C. Hay, S. Buchbinder, et al.
Efficient Processing of the Immunodominant, HLA-A*0201-Restricted Human Immunodeficiency Virus Type 1 Cytotoxic T-Lymphocyte Epitope despite Multiple Variations in the Epitope Flanking Sequences
J. Virol., December 1, 1999; 73(12): 10191 - 10198.
[Abstract] [Full Text]


Home page
J. Gen. Virol.Home page
E. Desmézières, Y. Jacob, M.-F. Saron, F. Delpeyroux, N. Tordo, and P. Perrin
Lyssavirus glycoproteins expressing immunologically potent foreign B cell and cytotoxic T lymphocyte epitopes as prototypes for multivalent vaccines
J. Gen. Virol., September 1, 1999; 80(9): 2343 - 2351.
[Abstract] [Full Text]


Home page
J. Immunol.Home page
M. C. Villacres and C. C. Bergmann
Enhanced Cytotoxic T Cell Activity in IL-4-Deficient Mice
J. Immunol., March 1, 1999; 162(5): 2663 - 2670.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L. M. Mylin
Context-Dependent Immunogenicity of an S206G-Substituted H-2Db-Restricted Simian Virus 40 Large T Antigen Epitope I Variant
J. Immunol., February 15, 1999; 162(4): 2171 - 2179.
[Abstract] [Full Text] [PDF]


Home page
J. Exp. Med.Home page
M. Theobald, T. Ruppert, U. Kuckelkorn, J. Hernandez, A. Haussler, E. A. Ferreira, U. Liewer, J. Biggs, A. J. Levine, C. Huber, et al.
The Sequence Alteration Associated with a Mutational Hotspot in p53 Protects Cells From Lysis by Cytotoxic T Lymphocytes Specific for a Flanking Peptide Epitope
J. Exp. Med., September 21, 1998; 188(6): 1017 - 1028.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
T.-M. Fu, L. M. Mylin, T. D. Schell, I. Bacik, G. Russ, J. W. Yewdell, J. R. Bennink, and S. S. Tevethia
An Endoplasmic Reticulum-Targeting Signal Sequence Enhances the Immunogenicity of an Immunorecessive Simian Virus 40 Large T Antigen Cytotoxic T-Lymphocyte Epitope
J. Virol., February 1, 1998; 72(2): 1469 - 1481.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1996 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1996 by The American Association of Immunologists, Inc. All rights reserved.